OPINION
Keeping digital pathology open: future frameworks
Ian Cadieux, Head of Quality and Regulatory, Proscia
Interoperability in digital pathology is about more than the ability to open an image file. It means giving pathologists a consistent, trusted experience as laboratories add scanners, displays, and connected systems. Selecting a digital pathology platform for primary diagnosis is a long-term, important decision impacting laboratory operations and the patients who depend on the results. Pathologists develop years of
familiarity with the software they use to review cases. The laboratory’s LIS, image archive, integrations, and future technology purchases form a technology ecosystem around the software. The digital pathology platform, therefore, has to meet a high bar when it is first deployed and continue meeting that bar as the laboratory’s equipment and workflows evolve. Our new FDA 510(k) clearance for
Concentriq AP-Dx responds to that reality. The clearance adds support for the Leica Aperio GT 450 DX slide scanner and, more importantly, authorises a Predetermined Change Control Plan, or PCCP, for adding additional FDA- cleared whole slide scanners and their associated image formats, as well as FDA-cleared pathology displays. It turns openness from an architectural principle into a repeatable, regulated process.
Regulatory framework Historically, adding a new scanner or diagnostic display to a cleared digital pathology platform has typically required a new 510(k) and an associated FDA review cycle before the new configuration could be offered for primary diagnosis. At the end of 2022, Section 515C was added to the
Federal Food, Drug, and Cosmetic Act, establishing the legal foundation for FDA to authorise plans for certain future device modifications. A PCCP describes the planned modifications to a device and how those modifications will be developed, validated, implemented, and assessed for their impact on safety and effectiveness. A change that would otherwise require a new 510(k) may then be implemented without a separate marketing submission when it is consistent with the FDA- authorised PCCP, resulting in a more efficient path to market. A PCCP is not a blank check. It
establishes defined boundaries: which types of changes are eligible, what evidence must be generated, what acceptance criteria must be met, how risks will be controlled, and how labelling will be updated. Every future component must still pass the applicable validation protocol before it can be added to the cleared system. The FDA has also invested in regulatory
science tools that make this type of evidence generation more standardised and predictable. One such tool, the Image Viewer Integrity Evaluation System (IVIES), provides a common, quantitative method for comparing how two whole slide imaging applications render the same image files at the pixel level. During the review of Concentriq AP-Dx, we confirmed our pixel-wise comparison results by also using the IVIES tool and incorporated the tool into our PCCP. It was a practical demonstration of how collaboration between regulators and manufacturers can make device review more repeatable and efficient. Together, the PCCP framework and
tools such as IVIES represent a thoughtful approach to technological change. As new FDA-cleared scanners and pathology displays enter the market, this framework gives us a defined way to evaluate them against predetermined requirements
About Ian Cadieux Ian Cadieux is Head of Quality and Regulatory at Proscia, the pathology AI company rewiring pathology for precision medicine across drug discovery, development, and diagnosis. Ian is a regulatory and quality leader who brings a deep engineering pedigree to the scale and commercialisation of software- enabled medical technologies. His 20-year plus background spans end-to-end product development, systems engineering, and cross- functional program management, culminating in executive leadership of global regulatory strategy, agile QMS transformations, and market authorisations.
www.proscia.com
and, when those requirements are met, support them more efficiently for laboratories.
Looking ahead The significance of this clearance extends beyond the next scanner or display we add. The evolution in regulatory science is increasingly important as pathology becomes more software-driven. Laboratories are adopting new capabilities, including new scanners, automation, AI-enabled devices, and other computational tools. We also expect computational biomarkers and companion diagnostics to play a growing role in matching patients with appropriate therapies. Those advances cannot reach their
full potential if every new tool requires a laboratory to replace or reconstruct the platform surrounding them because the manufacturer restricted the use to a closed system of specific components. Laboratories need open platforms that can connect images, clinical context, laboratory systems, and validated applications while continuing to satisfy the requirements of diagnostic use. That is the future we are working toward, alongside laboratories, technology partners, industry colleagues, and regulators.
Our new clearance is a significant
Laboratories need open platforms that can connect images, clinical context, laboratory systems, and validated applications
milestone in that commitment, but not the end. Standardised evaluation tools and PCCPs provide a framework to maintain interoperability in our rapidly advancing field. As pathology adds more AI-enabled devices and computational diagnostics in the years ahead, Proscia intends to keep applying that same framework, so laboratories can put each new advancement to work on the platform they already have, wherever authorisation allows, so that it can benefit patients sooner.
PPi September 2026
WWW.PATHOLOGYINPRACTICE.COM 5
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
